The objectives were to evaluate gabapentin add-on therapy in a large population under conditions close to real practice and to determine the therapeutic doses as reached with adaptable dosages. A 6-month multicentre, open-label study, involved addition of gabapentin to pre-existing treatment at the initial dosage of 1200 mg and subsequent adjustment between 900 and 2400 mg/day according to efficacy and tolerability. A study group of 610 adult patients, with partial epilepsy, persistent seizures and a median seizure frequency with a baseline of 7.2 per month were recruited; one-third had less than four seizures per month. Polypharmacy was frequent, with a mean of 2.3 concomitant drugs. After 6 months, 368 patients (62%) continued on gabapentin, at a mean dosage of 1739 mg/day with 44% of responders. On an intention-to-treat basis, median reduction in frequency was 21.2%, and the responder rate was 33.9%. The responder rate increased to 40.7% in the less severe subgroup receiving only one concomitant drug. Seventy-nine patients (13.4%) remained without seizures during the last evaluation period, versus nine (1.5%) during the baseline. Most of them had initially less than four seizures per month. The most frequent adverse effects, somnolence (29.3%), asthenia (14.6%), nausea (7.9%), ataxia (7.7%) and vertigo (7.2%), occurred rapidly after initial titration to 1200 mg/day, and were usually transitory. Weight gain (8.8%) seemed to be related to gabapentin dose. The combination of two recent drugs, vigabatrin and gabapentin, in 190 patients led to similar efficacy levels, with a tendency for more frequent somnolence and asthenia.
INTRODUCTION
Clinical experience with gabapentin is primarily based upon five double-blind studies conducted as add-on therapy in patients with refractory partial epilepsy'.
The development programme concentrated on parallel groups, involving a total of 307 patients who received a placebo and 485 patients who received fixed gabapentin dosages of 600,900, 1200 or 1800 mg/day for 12 weeks2-6. Besides these pivotal trials regarding efficacy, open-label, long-term studies have brought additional data about safety and maintenance of efficacy. Dosage adjustments were permitted, generally in the range of 600-2400 mg/day, although increases to as high as 3600 mg have been tested73 '. Most of the patients enrolled in the open studies, however, had previously participated in a placebo-controlled trial and its subsequent open-label extension, and had derived some benefit by showing improved seizure control and the absence of unacceptable adverse effects. In consequence the openlabel, long-term studies were only representative of a selected, enriched population of patients with refractory partial epilepsy. The development programme, allowing comparison of dosages ranging between 600 and 1800 mg/day, supported a dose-response relationship23 5. This has led to a strong tendency, in view of the good safety profile of gabapentin, to use higher dosages than in previous controlled studies. However, there is a relative lack of guidelines regarding the determination of the optimum therapeutic dose and the titration schedules.
The present study was designed to be conducted in conditions closer to actual clinical practice than the controlled studies or their open-label continuation, and had the following objectives.
1. To test gabapentin in a broad spectrum of patients with partial seizures which were not satisfactorily controlled by pre-existing anticonvulsant therapy. In particular, patients having persistent seizures at a relatively low frequency and who were not included in the controlled studies were eligible for the present study.
2. To determine the optimal therapeutic dosage when using non-fixed, adaptable dosages ranging between 900 and 2400 mg/day and a flexible titration phase.
3. To compare the tolerability and efficacy observed under these conditions with those observed in previous studies.
The study also provided information about the combination of new antiepileptic agents, since a substantial number of patients received vigabatrin as concomitant treatment.
METHODS
This study employed a multicentre, add-on, open design. The selection criteria were simplified so as to address the whole spectrum of patients seen in routine practice. In the same way, a short baseline and a flexible schedule for intermediate visits were used in order to limit the constraints of the protocol.
Study design
The protocol was approved by the local ethical committee and informed consent was obtained from each patient prior to study entry. Seizure frequency and clinical status were recorded during a 4-week baseline period, which was done either prospectively, or retrospectively if reliable data were available. The preexisting antiepileptic treatment had to remain constant during the baseline. Biological analyses were done at the end of the baseline. Gabapentin treatment was then initiated at the dosage of 1200 mg/day, which was reached in 3 days (600 mg on day 1; 900 mg on day 2; 1200 mg on day 3). Gabapentin was administered in multiples of 300-mg or 400-mg capsules. Thereafter, intermediate visits allowed the gabapentin treatment to be adjusted by increasing or decreasing the daily dosage between an upper limit of 2400 mg and a lower limit of 900 mg, according to efficacy and tolerability. Concomitant antiepileptic drugs could also be adjusted if this was considered clinically appropriate. A final visit was made at the end of a 6-month follow-up, except in the event of premature withdrawal. In the latter case, the last visit actually made by the patient was considered as the final visit. Seizure frequency during the preceding 4 weeks was recorded for efficacy evaluation.
Data analysis Inclusion criteria
To enter the study, patients had to have definite partial epilepsy with persistent seizures, as evaluated during the previous 3 months. However, in order to include a broad spectrum of patients with varying degrees of severity, there were no minimum requirements regarding seizure frequency. Patients had to be at least over 18 years of age, and be able to keep a diary to record their seizure count; seizure types (simple partial, complex partial or secondarily generalized) were recorded. Women were not pregnant or nursing, and those of childbearing age used a reliable method of contraception.
The number of concomitant antiepileptic drugs was not limited; new antiepileptic agents were, however, restricted to vigabatrin as other compounds, such as lamotrigine, were not available on the French market at the beginning of the study. Patients were excluded in the case of a progressive structural lesion in the central nervous system, severe liver or kidney insufficiency, a white blood cell count below 3000/mm3 and/or a neutrophil count below 1500/mm3, receipt of any other investigational drug within the previous month, or chronic alcohol or drug abuse. 2. Gabapentin dosages: each dosage modification and the reason were recorded; at the end of the 6-month study the investigators noted, for patients continuing on gabapentin, which daily dosage would subsequently be used: this dosage was then considered as the optimum therapeutic dose for a given patient.
3. Efficacy: measures of seizure reduction were the percentage change in seizure frequency, responder rate, and the response ratio. The percentage change in seizure frequency was the difference between seizure frequency in the final 4-week period of gabapentin treatment and baseline seizure frequency, expressed as a percentage of baseline frequency. The responder rate was the percentage of patients with a reduction of 50% or more in seizure frequency during the 4-week period preceding the final visit as compared with the baseline. The response ratio" was calculated as the difference between the seizure frequency during the last 4-week period of the study and the baseline seizure frequency, divided by the sum of the two frequencies. A response ratio value of -0.33 represents a 50% reduction in seizure frequency. The use of the response ratio allowed patients who did not experience any seizures at all or any of the seizure types under consideration during the baseline period to be included in the efficacy analysis.
RESULTS

Patient characteristics
Of the 628 patients who entered the study, 18 were excluded for various protocol violations; 610 thus completed the study. The population had a mean age of 37.2 years (range 18-76 years) and included 313 men (5 1.3%) and 297 women (48.7%). Mean duration of the disease was 22.7 years (range O-62 years). Localization of partial epilepsy was distributed as follows: temporal 48.6%, frontal 14.4%, parietal 5.1%, occipital 2.3%, multifocal 15.9%, undetermined 13.6%.
The median baseline seizure frequency per month was 7.2 (range O-338); 34.1% of the patients had fewer than four seizures per month, 24.5% from 4 to 9, 18.8% from 10 to 19 and 22.6% had 20 and over seizures per month.
Most patients had previously been treated with conventional anticonvulsant agents, as monotherapy or polytherapy, and 19% of them had taken part in a previous drug trial. At the start of the present study, the concomitant antiepileptic drugs were carbamazepine in 73% of patients, vigabatrin in 35%, phenobarbitone in 35%, benzodiazepines in 34%, sodium valproate in 28%, phenytoin in 22% and others in 1%. The mean number of concomitant antiepileptic drugs was 2.3, 17.4% of patients receiving pre-existing treatment with one drug, 44.6% with two drugs, and 38% with three drugs or more.
The sub-group (n = 106) receiving only one concomitant antiepileptic drug had a slightly, but significantly, different profile from the remainder of the patients: the mean duration of disease was 19.0 years, the median baseline seizure frequency was 5.3 seizures per month, and 42.9% of these patients had fewer than four seizures per month. These characteristics indicate a less severe disease profile than for the 504 patients receiving two or more drugs concomitantly.
Gabapentin dosages and titration phase
At the end of the 6-month follow-up period 368 patients (62% of the total) continued on gabapentin; their mean gabapentin dosage was 1739 mg/day (range 600-3200; median 1600). The values of the therapeutic dose were distributed as follows ( Fig. 1 ): 29% from 900 to 1200, 23% from 1200 to 1600, 22% from 1600 to 2000 and 24% over 2000. A few deviations from the protocol led to some lower (600 mg (n = 3), 800 mg (IZ = 3)) and higher (2800 (n = I), 3200 (n = 3)j daily dosages. Multiples of 400 mg capsules represented the large majority of the treatments.
The titration phase is represented in Fig. 2 . The therapeutic dose was reached in a median time of 99 days (range 3-25). The median duration to increase the dosage to 1600 mg/day was 59 days (range 4-168) for the 382 patients in whom this dosage was reached, 84 days (range 14-178) to 2000 mg/day for 221 patients and 92 days (range 24-178) to 2400 mg/day for 109 patients. The possibility of reducing gabapentin dosage in the event of adverse effects was used in 95 patients (15.6%). Out of these 95 cases, 68 (72%) completed the 6-month study and 52 continued on the drug. Thus, among the 368 patients continuing on gabapentin, 14% underwent a dosage reduction before reaching their optimum therapeutic dosage. The duration of titration up to 1600, 2000 or 2400 mg/day for the 95 patients did not differ from that of patients for whom no gabapentin dosage decrease was considered appropriate.
Changes in seizure frequency
Results for the three primary efficacy parameters, as analysed on an intention-to-treat basis, are shown in Table 1 . Taking all seizure types together, the median percentage reduction in seizure frequency was 21.2% and the percentage of responders 33.9%; the response ratio had a mean value of -0.163. The results for all patients were analysed according to four categories of seizures frequency during the baseline. These results included median percentage change in seizure frequency, responder rate and mean response ratio (Table 2) .
Sub-group analysis according to the number of concomitant antiepileptic drugs showed that the group of patients receiving one concomitant antiepileptic drug had a reduction in median seizure frequency of -40.7%, a percentage of responders of 40.6%, and a response ratio of -0.287. Nine patients (1.5%) did not present any seizures during the baseline. This number rose to 79 (13.4%) during the final evaluation period. Most of these patients (n = 48) had a baseline seizure frequency of fewer than four seizures per month, representing 23.1% of this sub-group (Table 2). Premature discontinuation of gabapentin due to lack of efficacy occurred in 51 patients (8.4%). In 124 others (20.3%) gabapentin was discontinued after the end of the study because the benefits were not considered to be sufficiently consistent by the patient or the physician.
Finally, regarding the 368 patients (62% of the total) in whom gabapentin was continued at the end of the 6-month study, the mean responder rate was 44.0%. The relationship between dose and response could not be investigated due to the possibility for adapting doses according to tolerability and seizure control.
Tolerability
Adverse effects occurred in 62% of the patients, somnolence (29.3%), asthenia (14.6%), weight gain (8.8%), ataxia (7.7%) and vertigo (7.2%) being the most frequently observed (Table 3) . Adverse effects leading to premature discontinuation of gabapentin were observed in 57 patients (9.3% of the total): somnolence (n = 24, 3.9%), asthenia (n = 14, 2.3%), nausea-vomiting (n = 13, 2.1%), ataxia (n = 10, 1.6%) and vertigo (n = 8, 1.3%) were the most frequent. The two main adverse effects which led to a decrease of gabapentin dosage in 95 patients were add-on therapy 59 also somnolence (56%) and asthenia (28%). The delay in appearance and the duration of the most frequent adverse effects had median values (delay in appearance per duration, in days) of 9138 for somnolence, 12/48 for asthenia, 7/14 for vertigo, 21126 for headache, and 1219 for nausea. The occurrence of adverse effects, their number and their nature were not influenced by the dose: the percentages of patients presenting any kind of adverse effects were similar in the four categories of dosage, varying from 53 to 64%; the mean number of adverse effects ranged from 2.3 to 2.6 (Table 3) .
Weight gain was examined in detail, as this adverse effect was not reported in controlled or in continuation studies. Weight gain occurred in 54 of our patients (8.80/o), the average gain being 5.4 kg. This adverse effect occurred neither in patients receiving concomitantly sodium valproate and/or vigabatrin (7.7%) nor in those who were not receiving either of these drugs (10%) both of which are known to induce weight gain. A dose-effect relation was observed for weight gain, as 8.0, 6.3, 9.7 and 15.2% of the patients were affected in the dose categories of 1200, 1600, 2000 and 2400 mg/day, respectively (Table 3) .
Severe adverse events occurred in 45 patients (7.4%) and included falls and fractures, surgery, personality disorders, somnolence, and miscellaneous disturbances.
Gabapentin-vigabatrin polypharmacy
This study, conducted in a country where vigabatrin was widely used in resistant partial epilepsy, provided an opportunity to collect data on the association of vigabatrin and gabapentin. A total of 190 patients who were taking vigabatrin in their regimen received gabapentin as add-on therapy. This subpopulation was similar to the global population in terms of distribution of seizure frequencies, but differed regarding baseline polypharmacy, as only 3.2% of these patients had one antiepileptic drug, versus 17.4% in the global population. The responder rate in the vigabatrin-gabapentin group (32.8%) was similar to that in the rest of the study population (34.3%). Adverse effects differed slightly, with somnolence being reported in 34.2 and 26.9% (P = 0.07), asthenia in 17.4 and 13.3% of the vigabatrin-gabapentin group and the rest of the study population, respectively.
DISCUSSION
A solid background of clinical data on the efficacy and safety of gabapentin has allowed it to obtain marketing approval in several countries, including France in October 1994. At that stage in its development, however, information was still lacking in certain areas, especially regarding therapeutic dose and titration schedules, as is often the case with new antiepileptic drugs . 'e This observational study was undertaken to address these issues. It was designed to be closer to normal clinical practice than controlled studies and their extensions in terms of patient selection and dosage flexibility, and thus provide complementary data on the tolerability and efficacy figures to be expected in these different conditions. It was initiated and mostly conducted during the delay of 15 months between approval and actual availability of gabapentin on the market.
Patient characteristics
The 610 patients analysed in this study were selected on the basis of their having unsatisfactorily controlled partial epilepsy, regardless of the frequency and type of the persistent seizures. By comparison, the pa- tients in the three pivotal controlled studies had an average of at least four partial seizures per month during the 3 months preceding the baseline and the median seizure frequency ranged between 10 and 13 seizures per month during the baseline. This median seizure frequency was lower (7.2 seizures per month) in the present study, which used a shorter baseline of 1 month, and one-third of the patients would not have been selected for the controlled studies due to their having fewer than four seizures per month. From this point of view our population tended to be globally less severely affected than the populations in the controlled studies. The number of concomitant antiepileptic drugs was, however, higher as it was not limited to two by the selection criteria: 38% had a three-drug treatment before introduction of gabapentin. This context of heavy polypharmacy makes interpretation of tolerability more difficult, but probably did not interfere with the efficacy as there are no pharmacokinetic interactions between gabapentin and other antiepileptic drugs", '*. The present study protocol, being widely applicable and easy to follow, made it possible to define the profile of the patients who are the first-line candidates for this new drug.
Therapeutic dose
The controlled studies, in parallel groups, used different fixed dosages of 600,900,1200 and 1800 mg/day and showed a significant dose-response correlation, suggesting that higher doses may increase the gain in seizure control. However, relatively few patients (n = 54) received 1800 mg/day double-blind5. Subsequent open studies employing doses of up to 2400 mg/day showed long-term safety and suggested a good maintenance of efficacy for up to 2 years7,*. However, in these continuations of the placebo-controlled trials, the higher doses were reached after a titration period of several months, and only in those patients who had derived benefit from the initial phases in the absence of marked adverse effects. They were thus representative of a selected, enriched population.
Determining the optimum therapeutic dose for a given patient is a point of practical importance. It is common clinical practice to increase the antiepileptic drug dosage step by step until reaching a satisfactory response or unacceptable adverse effects. However, the range of gabapentin dosage tested in previous studies varied from 600 to 3600 mg/day, and serum concentration measurements did not prove helpful12. Thus, some guidelines regarding the mean value of gabapentin dosage that should be targeted as add-on therapy would be helpful.
The present observational value of 1739 mg/day indicates the mean dosage which allowed a clinical response to be obtained in our population. This mean dosage represents a marked increase in comparison to controlled studies, where the mean dosage was about 1100 mg/day, and confirms the current tendency to use higher dosages. This value may serve as a firstintention target and the dosage can subsequently be increased to over 2400 mg/day in cases difficult to treat.
Efficacy
Efficacy figures were comparable to those observed in the controlled studies. Considering all 610 patients, we observed a median reduction in seizure frequency (all seizure types) of 21.2%, a responder rate of 33.9% and a mean response ratio of -0.163, versus 31.2%, 26.4% and -0.233, respectively, in the 1800 mg/day group of the controlled study5. Individualization of the different seizure types confirmed the efficacy upon complex partial and secondarily generalized seizures. At the end of the 6-month period, the percentage of responders was 44% among patients continuing on the drug.
In order to evaluate the impact of gabapentin on cases of lesser severity than in the controlled studies we considered two sub-populations. In the subpopulation with an initial seizure rate of less than four per month, the median change in seizure frequency and the mean response ratio were very close to zero. This unexpected lack of global change may be due to the very strong impact, in terms of percentage, of a variation of only one or two seizures from the baseline in this range of seizure frequency. Including patients regardless of the number of their seizures during the baseline, and in particular the absence of a minimum number, probably reduces the effectiveness of the phenomenon of regression towards the mean which increases the probability of having fewer seizures during the period following the baseline13. Nevertheless the responder rate was about 30% in this sub-population. Furthermore, among the 79 patients in the study who remained seizure free during the final evaluation period, 48 (61%) belonged initially to this category of less than four seizures per month. In spite of the short evaluation period, these data suggest that good seizure control can be expected in patients with less severe partial epilepsy. Another way of identifying a sub-group of lesser severity was to consider those patients who had only one concomitant antiepileptic drug. Taken together, a median seizure frequency reduction of 40.7%, a percentage of responders of 40.6%, and a -0.287 response ratio suggest that the expected level of seizure control with gabapentin increases as we move along the spectrum of partial epilepsies toward the cases with shorter disease duration and less frequent seizures.
Tolerability
This study confirmed the high degree of tolerability of gabapentin, and adverse effects were similar in nature and frequency to those reported elsewhere12. Some additional information is provided, however. Most of the main adverse effects, such as somnolence, asthenia, ataxia or vertigo, occurred relatively rapidly, during the first weeks after gabapentin introduction, and their duration was limited. Moreover, their occurrence, their mean number per patient and their nature were not related to the dosage when it was between 1200 and 2400 mg/day. This suggests that these types of adverse effects were much more the consequence of the rapid initial titration to 1200 mg/day than the consequence of the following increments and the titration curve is in keeping with this observation. A more gradual introduction of gabapentin, where this is compatible with the patient's status, could therefore result in less marked somnolence and asthenia during the first weeks. Weight gain was not a rare occurrence as it was observed in 8.8% of the patients: a dose-adverse effect correlation existed between 1200 and 2400 mg/day, the percentage of affected patients increasing from 8 to 15%. This adverse effect occurred in a context of multiple-drug therapy and we looked at possible roles for the concomitant antiepileptic drugs. The simultaneous presence of sodium valporate and/or vigabatrin, both already known to induce weight gain, had no influence.
Polypharmacy
The number of concomitant antiepileptic drugs was not limited in the present study and, as a consequence of this selection process, the patients' regimen prior to gabapentin introduction comprised a single drug in 17.4% of cases, two drugs in 44.6%, and three drugs in 38%, leading in this latter case to a fourdrug treatment in conditions close to current practice. The investigators considered the 6-month duration of the study to be insufficient to attempt to reduce these polypharmacies, even in cases with a satisfactory response.
Among the various drug regimens, the association of gabapentin and vigabatrin occurred in 190 patients (31.1%). The availability of these two recent antiepileptic drugs in several countries, raises the question of possible advantages and disadvantages of combining them14. They both have a very good pharmacokinetic profile, with no drug-to-drug interaction. They would appear to have different mechanisms of action, although they both result in increased brain gamma-aminobutyric acid (GABA) levels. Vigabatrin acts as an irreversible inhibitor of the enzyme GABAtransaminase'" and thus considerably enhances brain GABA levels. The mode of action of gabapentin is largely unknown, although it binds to a specific receptor in the brain and may inhibit voltage-dependent sodium currents16. Recent reports have suggested that gabapentin promotes the release of GABA from neurons and glia, inducing an increase in extracellular GABA. Magnetic resonance spectroscopy" studies have confirmed that gabapentin increases human brain GABA levels, but to a lesser extent than vigabatrin18. In terms of clinical response, those patients in the present study receiving the gabapentinvigabatrin combination presented a very similar percentage of responders to the others. In terms of tolerability, somnolence and asthenia were slightly more frequent, but the degree of polypharmacy was higher in patients under gabapentin and vigabatrin. In conclusion, polypharmaceutical regimens including vigabatrin and gabapentin showed neither increased efficacy nor clearly additive adverse effects.
The present study included a large number of patients covering a wide range of partial epilepsy. While one section of the population had the same characteristics as the patients included in the controlled studies, the remainder comprised patients with less severe epilepsy in terms of seizure frequency, thus representing a step towards a wider use of gabapentin as adjunctive therapy. The percentage improvement in seizure control was higher in these less severe cases than in the other patients. Some ongoing studies have enrolled patients in whom gabapentin is given as first add-on therapy .
l9 These studies should help to define a further part of the spectrum of patients likely to benefit from adjunctive gabapentin therapy and to determine the corresponding degree of improvement in seizure control that can be expected.
